Clinical Research Papers:
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma
Metrics: PDF 1353 views | HTML 1530 views | ?
Qingqing Cai1,2, Yiming Chen2, Dehui Zou3, Liang Zhang2, Maria Badillo2, Shouhao Zhou 4, Elyse Lopez2, Wenqi Jiang1, Huiqiang Huang1, Tongyu Lin1, Jorge Romaguera 2 and Michael Wang2,5
1 Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
2 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3 Lymphoma and Myeloma Center, Institute of Hematology and Blood Diseases Hospital, State Key Lab of Experimental Methods of Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China
4 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Michael Wang, email:
Keywords: Clinical outcomes; Lenalidomide, Relapsed lymphoma, Rituximab, Stem cell transplantation
Received: June 02, 2014 Accepted: July 24, 2014 Published: July 25, 2014
We retrospectively compared outcomes of patients with relapsed/refractory non-Hodgkin lymphoma (NHL) who underwent stem cell transplantation (SCT) with stable disease or better following a novel combination of lenalidomide and rituximab (LR) treatment and did not undergo SCT in a phase I/II clinical trial. We retrospectively compared outcomes of patients who underwent SCT with that of patients who had stable disease or better following LR treatment and did not undergo SCT. Twenty-two patients enrolled in LR clinical trial and undergone SCT were identified, 13 with mantle cell lymphoma (MCL) and nine with large B-cell lymphoma (LBCL). All patients who underwent SCT achieved complete response. In the MCL subset, there were no significant differences between SCT and non-SCT groups except that non-SCT patients were older and had a higher mantle-cell international prognostic index score. There was no difference between SCT-group and non-SCT-group in response duration (P=0.3), progression-free survival (PFS) (P=0.304) and overall survival (OS) (P=0.87). In LBCL subgroup, there were no significant differences between two groups except that non-SCT group had a higher international prognostic index score. Patients with LBCL who underwent SCT had significantly longer response duration (P=0.001), PFS (P=0.000), and OS (P=0.003) than the non-SCT group. The novel therapeutic combination offers a bridge to SCT in patients with relapsed/refractory aggressive B-cell NHL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.